Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis

Clinical and Experimental Metastasis

Volumn 28, Issue 4, 2011, Pages 405-411

  Yuasa, Takeshi ^a   Urakami, Shinji ^a   Yamamoto, Shinya ^a   Yonese, Junji ^a   Saito, Kazutaka ^a   Takahashi, Shunji ^a   Hatake, Kiyohiko ^a   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bone metastasis; Outcome; Prognostic factor; Renal cell cancer; Sunitinib

Indexed keywords

NEXAVAL; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79955524407     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9379-7     Document Type: Article

References (25)

1. RJ Motzer MD Michaelson BG Redman, et al. 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24 16330672 10.1200/JCO.2005.02.2574 1:CAS:528:DC%2BD28Xot1ChtA%3D%3D (Pubitemid 46630489)
2. S Négrier B Escudier F Gomez, et al. 2002 Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie Ann Oncol 13 1460 1468 12196373 10.1093/annonc/mdf257
3. S Naito N Yamamoto T Takayama, et al. 2010 Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients Eur Urol 57 317 325 19136199 10.1016/j.eururo. 2008.12.026 1:CAS:528:DC%2BC3cXls12ktLg%3D
4. MA Kuczyk AG Anastasiadis R Zimmermann, et al. 2005 Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer BJU Int 96 721 727 16144527 10.1111/j.1464-410X.2005.05771.x quiz i-ii (Pubitemid 41391417)
5. Y Toyoda N Shinohara T Harabayashi, et al. 2007 Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone Eur Urol 52 163 168 17098353 10.1016/j.eururo.2006.10.060 (Pubitemid 46802996)
6. Lipton A (2004) Management of bone metastasis in patients with renal cell carcinoma and other malignancies of the genitourinary tract. In: Kantoff P, Saad F, Smith MR (eds) Management of skeletal complications of prostate cancer and other genitourinary malignancies. FA Davis Co, Philadelphia, pp 207-234
7. RJ Motzer J Bacik BA Murphy, et al. 2002 Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 289 296 11773181 10.1200/JCO.20.1.289 1:CAS:528:DC%2BD38XnsFeqtg%3D%3D (Pubitemid 34032623)
8. A Lipton A Colombo-Berra RM Bukowski, et al. 2004 Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid Clin Cancer Res 10 6397S 6403S 15448038 10.1158/1078-0432.CCR-040030 1:CAS:528:DC%2BD2cXnvVOjtr0%3D (Pubitemid 39287498)
9. B Escudier T Eisen WM Stadler, et al. 2007 TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
10. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alpha in metastatic renal-cell carcinoma N Engl J Med 356 115 124 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
11. RB Payne AJ Little RB Williams JR Milner 1973 Interpretation of serum calcium in patients with abnormal serum proteins Br Med J 4 643 646 4758544 10.1136/bmj.4.5893.643 1:STN:280:DyaE2c%2FksVKmuw%3D%3D
12. A Bamias A Karadimou S Lampaki, et al. 2010 Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model BMC Cancer 10 45 20163744 10.1186/1471-2407-10-45
13. TK Choueiri JA Garcia P Elson, et al. 2007 Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 543 550 17577222 10.1002/cncr.22827 1:CAS:528:DC%2BD2sXpt1yqu70%3D (Pubitemid 47106142)
14. S Patil RA Figlin TE Hutson, et al. 2010 Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 295 300 20657034 10.1093/annonc/mdq342
15. PP Lin AN Mirza VO Lewis, et al. 2007 Patient survival after surgery for osseous metastases from renal cell carcinoma J Bone Joint Surg Am 89 1794 1801 17671020 10.2106/JBJS.F.00603 (Pubitemid 47229888)
16. ST Jung MA Ghert JM Harrelson SP Scully 2003 Treatment of osseous metastases in patients with renal cell carcinoma Clin Orthop Relat Res 409 223 231 12671506 10.1097/01.blo.0000059580.08469.3e (Pubitemid 36417733)
17. J Lee D Hodgson E Chow, et al. 2005 A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma Cancer 104 1894 1900 16177996 10.1002/cncr.21410 (Pubitemid 41513172)
18. D Wilson L Hiller L Gray, et al. 2003 The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma Clin Oncol (R Coll Radiol) 15 400 407 1:STN:280:DC%2BD3svpt1Ogug%3D%3D (Pubitemid 37161704)
19. T Kijima Y Fujii T Suyama, et al. 2009 Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate BJU Int 103 620 624 18990143 10.1111/j.1464-410X.2008.08124.x 1:CAS:528:DC%2BD1MXktFGjsrk%3D
20. T Yuasa S Kimura E Ashihara, et al. 2007 Zoledronic acid - a multiplicity of anti-cancer action Curr Med Chem 14 2126 2135 17691952 10.2174/ 092986707781389600 1:CAS:528:DC%2BD2sXptV2hs7c%3D (Pubitemid 47578153)
21. M Gnant B Mlineritsch W Schippinger, et al. 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 679 691 19213681 10.1056/NEJMoa0806285 1:CAS:528:DC%2BD1MXhvVyisbk%3D
22. R Aft M Naughton K Trinkaus, et al. 2010 Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 421 428 20362507 10.1016/S1470-2045(10)70054-1 1:CAS:528:DC%2BC3cXlsFSitrw%3D
23. J Zołnierek P Nurzyński P Langiewicz, et al. 2010 Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases J Cancer Res Clin Oncol 136 371 378 19711099 10.1007/s00432-009-0664-7
24. ME Gore C Szczylik C Porta, et al. 2009 Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 757 763 19615940 10.1016/S1470-2045(09)70162-7 1:CAS:528:DC%2BD1MXptlalsrc%3D
25. Y Tomita N Shinohara T Yuasa, et al. 2010 Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma Jpn J Clin Oncol 40 1166 1172 20713418 10.1093/jjco/hyq146